NCT07759674CompletedPhase 4
Relationship Between Metformin Treatment, Anemia, and Erythropoietin Levels in Women With Polycystic Ovary Syndrome in Jordan
Effects of Routine Metformin Therapy on Insulin Resistance, Iron Metabolism, Erythropoietin, Lipid Profile, and Hematological Parameters in Jordanian Women With Polycystic Ovary Syndrome: A Prospective Longitudinal Interventional Study
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This prospective longitudinal interventional study aims to evaluate the effects of routine metformin therapy on metabolic, iron-related, erythropoietin, lipid, and hematological parameters in adult women with polycystic ovary syndrome (PCOS). Participants diagnosed with PCOS according to established diagnostic criteria receive routine metformin therapy for six months as part of standard clinical care. Clinical and laboratory assessments are performed at baseline, three months, and six months to evaluate changes in insulin resistance, fasting blood glucose, fasting serum insulin, serum ferritin, serum iron, erythropoietin (EPO), lipid profile, and hematological indices. The study also examines the relationships between metabolic, iron-related, and hematological biomarkers during metformin treatment.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 7 Aug 2026
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- Jerash Private University
- NCT number
- NCT07759674
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 25
- From 1 Jun 2023 to the primary completion date, 1 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of type 1 diabetes mellitus or established type 2 diabetes requiring insulin therapy.
- History of chronic kidney disease, chronic liver disease, hematological disorders, malignancy, or other severe systemic diseases.
- Known hypersensitivity or contraindication to metformin. Inability or unwillingness to complete the scheduled follow-up assessments.
Lab values
- Current use of medications known to affect glucose metabolism, iron metabolism, erythropoietin levels, or hematological parameters within the previous three months, other than routine metformin prescribed as part of the study.
Other
- Pregnancy or breastfeeding.
- Participation in another interventional clinical trial during the study period.
Who the study is looking for
- Women aged 18-45 years.
- Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam diagnostic criteria.
- Eligible for routine metformin therapy as determined by the treating gynecologist.
- Willing and able to provide written informed consent.
- Willing to attend scheduled follow-up visits and complete all study assessments over the six-month study period.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ministry of Health Primary Healthcare Centers Coordinator of this site? Confirm its status | Amman | Jordan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.